港股異動 | 復星醫藥高開3.28% 子公司獲MimiVax授權許可使用SurVaxM
格隆匯11月15日丨復星醫藥(2196.HK)高開3.28%,報23.65港元,暫成交217萬港元,最新總市值606億港元。復星醫藥前日(13日)晚間發公告稱,公司控股子公司復星醫藥產業獲得MimiVax, LLC許可,在區域內(即中國大陸、香港及澳門特別行政區)及領域內(即膠質母細胞瘤以及其他腫瘤和非腫瘤適應症的治療和預防)使用其專有知識(know-how)和專利(但不包括製造信息及相關專利)獨家臨牀開發和商業化(包括進口、銷售,但不包括製造)腫瘤免疫治療產品SurVaxM。中泰證券曾發研報指,復星醫藥控股子公司Gland計劃推進海外上市,生物藥、小分子創新藥不斷取得進展,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.